Following the transaction, Borgeson directly owns 6,429,863 shares of Recursion Pharmaceuticals. The company, while holding more cash than debt with a current ratio of 4.6, is quickly burning through ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Furthermore, Recursion Pharmaceuticals plans to present updated clinical data from the TUPELO trial during a webinar on December 8, 2025. This presentation will provide further insights into the ...
OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...
Abstract: This paper studies the estimation of dynamic route choice behavior of drivers with incomplete fixed location-based sensor data, such as radio frequency identification (RFID) data. Unlike ...
The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...
The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results